(FDMT) 4D Molecular Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 437m USD | Total Return: 120% in 12m

Gene Therapies, Viral Vectors, Retinal Therapeutics, Pulmonary Therapeutics
Total Rating 39
Safety 49
Buy Signal -0.72
Biotechnology
Industry Rotation: -12.2
Market Cap: 437M
Avg Turnover: 5.61M
Risk 3d forecast
Volatility76.6%
VaR 5th Pctl12.3%
VaR vs Median-2.50%
Reward TTM
Sharpe Ratio1.25
Rel. Str. IBD73.8
Rel. Str. Peer Group44
Character TTM
Beta1.073
Beta Downside1.707
Hurst Exponent0.440
Drawdowns 3y
Max DD93.00%
CAGR/Max DD-0.24
CAGR/Mean DD-0.38
EPS (Earnings per Share) EPS (Earnings per Share) of FDMT over the last years for every Quarter: "2021-03": -0.61, "2021-06": -0.28, "2021-09": -0.82, "2021-12": -0.85, "2022-03": -0.82, "2022-06": -0.87, "2022-09": -0.79, "2022-12": -0.84, "2023-03": -0.88, "2023-06": -0.77, "2023-09": -0.24, "2023-12": -0.75, "2024-03": -0.66, "2024-06": -0.63, "2024-09": -0.79, "2024-12": -0.9, "2025-03": -0.86, "2025-06": -0.98, "2025-09": -1.01, "2025-12": 0.43, "2026-03": -1.01,
Last SUE: -0.37
Qual. Beats: 0
Revenue Revenue of FDMT over the last years for every Quarter: 2021-03: 2, 2021-06: 14.58, 2021-09: 1.366, 2021-12: 0.092, 2022-03: 1.219, 2022-06: 0.162, 2022-09: 0.5, 2022-12: 1.247, 2023-03: 0.298, 2023-06: 0.239, 2023-09: 20.204, 2023-12: -0.019, 2024-03: 0.028, 2024-06: 0.005, 2024-09: 0.003, 2024-12: 0.001, 2025-03: 0.014, 2025-06: 0.015, 2025-09: 0.09, 2025-12: 85.09, 2026-03: 3.047,
Rev. CAGR: -39.03%
Rev. Trend: -12.8%
Last SUE: 0.03
Qual. Beats: 0

Warnings

Share dilution 22.1% YoY

Altman Z'' -15.00 < 1.0 - financial distress zone

Volatile Below Avwap Earnings

Tailwinds

No distinct edge detected

Description: FDMT 4D Molecular Therapeutics

4D Molecular Therapeutics (FDMT) is a late-stage biotechnology firm specializing in gene therapy via its proprietary Therapeutic Vector Evolution platform. The company utilizes directed evolution to engineer synthetic adeno-associated virus (AAV) vectors designed to deliver genetic payloads more efficiently than naturally occurring viruses. Its primary clinical focus is 4D-150, an intravitreal treatment for retinal vascular diseases including wet age-related macular degeneration and diabetic macular edema.

The company operates within the high-risk, high-reward gene therapy sector, where business models typically rely on heavy R&D investment and strategic partnerships to navigate multi-phase clinical trials. FDMT currently maintains a collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. Beyond ophthalmology, the pipeline includes 4D-710 for cystic fibrosis and preclinical candidates targeting geographic atrophy and lung disease.

To better understand how these clinical milestones might affect long-term valuation, consider reviewing the latest technical data on ValueRay. 4D Molecular Therapeutics was founded in 2013 and is headquartered in Emeryville, California.

Headlines to Watch Out For
  • Clinical trial results for 4D-150 determine competitive viability in wet AMD market
  • FDA design designations accelerate regulatory timeline for lead gene therapy candidates
  • Cash runway and burn rate dictate timing of future equity dilution
  • Strategic partnership milestones with Otsuka Pharmaceutical influence non-dilutive revenue streams
  • Manufacturing scalability of proprietary AAV vectors impacts long-term gross margin potential
Piotroski VR‑10 (Strict) 0.0
Net Income: -160.9m TTM > 0 and > 6% of Revenue
FCF/TA: -0.25 > 0.02 and ΔFCF/TA 5.08 > 1.0
NWC/Revenue: 410.2% < 20% (prev 1.33m%; Δ -1.33m% < -1%)
CFO/TA -0.25 > 3% & CFO -129.4m > Net Income -160.9m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 9.34 > 1.5 & < 3
Outstanding Shares: last quarter (68.1m) vs 12m ago 22.10% < -2%
Gross Margin: -12.45% > 18% (prev -1.54k%; Δ 152k% > 0.5%)
Asset Turnover: 17.16% > 50% (prev 0.00%; Δ 17.15% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -15.00
A: 0.71 (Total Current Assets 405.4m - Total Current Liabilities 43.4m) / Total Assets 512.9m
B: -1.53 (Retained Earnings -785.1m / Total Assets 512.9m)
C: -0.35 (EBIT TTM -179.5m / Avg Total Assets 514.3m)
D: -12.86 (Book Value of Equity -785.2m / Total Liabilities 61.1m)
Altman-Z'' Score: -16.21 = D
What is the price of FDMT shares? As of May 21, 2026, the stock is trading at USD 8.47 with a total of 510,245 shares traded.
Over the past week, the price has changed by -18.95%, over one month by -15.89%, over three months by -6.10% and over the past year by +120.00%.
Is FDMT a buy, sell or hold? 4D Molecular Therapeutics has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy FDMT.
  • StrongBuy: 5
  • Buy: 4
  • Hold: 2
  • Sell: 0
  • StrongSell: 1
What are the forecasts/targets for the FDMT price?
Analysts Target Price 28.2 233.2%
4D Molecular Therapeutics (FDMT) - Fundamental Data Overview as of 20 May 2026
P/S = 4.9556
P/B = 0.9678
Revenue TTM = 88.2m USD
EBIT TTM = -179.5m USD
EBITDA TTM = -179.2m USD
Long Term Debt = 21.4m USD (from capitalLeaseObligations, last fiscal year)
Short Term Debt = 5.49m USD (from shortTermDebt, last quarter)
Debt = 26.9m USD (corrected: LT Debt 21.4m + ST Debt 5.49m)
Net Debt = -364.0m USD (recalculated: Debt 26.9m - CCE 390.9m)
Enterprise Value = 73.3m USD (437.3m + Debt 26.9m - CCE 390.9m)
 Interest Coverage Ratio = unknown (Ebit TTM -179.5m / Interest Expense TTM 0.0)
 EV/FCF = -0.56x (Enterprise Value 73.3m / FCF TTM -130.1m)
 FCF Yield = -177.4% (FCF TTM -130.1m / Enterprise Value 73.3m)
 FCF Margin = -147.4% (FCF TTM -130.1m / Revenue TTM 88.2m)
 Net Margin = -182.3% (Net Income TTM -160.9m / Revenue TTM 88.2m)
Gross Margin = -12.45% ((Revenue TTM 88.2m - Cost of Revenue TTM 99.2m) / Revenue TTM)
Gross Margin QoQ = 32.56% (prev none%)
Tobins Q-Ratio = 0.14 (Enterprise Value 73.3m / Total Assets 512.9m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 26.9m)
Taxrate = 21.0% (US default 21%)
NOPAT = -141.8m (EBIT -179.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 9.34 (Total Current Assets 405.4m / Total Current Liabilities 43.4m)
Debt / Equity = 0.06 (Debt 26.9m / totalStockholderEquity, last quarter 451.8m)
 Debt / EBITDA = 2.03 (negative EBITDA) (Net Debt -364.0m / EBITDA -179.2m)
 Debt / FCF = 2.80 (negative FCF - burning cash) (Net Debt -364.0m / FCF TTM -130.1m)
 Total Stockholder Equity = 436.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -31.28% (Net Income -160.9m / Total Assets 512.9m)
RoE = -36.83% (Net Income TTM -160.9m / Total Stockholder Equity 436.8m)
RoCE = -39.18% (EBIT -179.5m / Capital Employed (Equity 436.8m + L.T.Debt 21.4m))
 RoIC = -32.85% (negative operating profit) (NOPAT -141.8m / Invested Capital 431.8m)
 WACC = 9.19% (E(437.3m)/V(464.2m) * Re(9.76%) + D(26.9m)/V(464.2m) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 91.11 | Cagr: 27.89%
 [DCF] Fair Price = unknown (Cash Flow -130.1m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.37 | # QB: 0
Revenue Correlation: -12.83 | Revenue CAGR: -39.03% | SUE: 0.03 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.01 | Chg30d=-2.73% | Revisions=-17% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-1.01 | Chg30d=-3.32% | Revisions=+0% | Analysts=8
EPS current Year (2026-12-31): EPS=-4.03 | Chg30d=-5.34% | Revisions=+0% | GrowthEPS=-66.5% | GrowthRev=-86.4%
EPS next Year (2027-12-31): EPS=-3.72 | Chg30d=+3.40% | Revisions=-9% | GrowthEPS=+7.6% | GrowthRev=+50.9%
[Analyst] Revisions Ratio: -17%